AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00906971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diaphragmatic breathing, isometric training of the abdominal muscles and abdominal massage
Description: Exercises will be conducted by one physiotherapist. A one-minute rest period will be observed between each series. Isometric training of the abdominal muscles: This will consist of a contraction of the upper abdomen muscle and diaphragm and the simultaneous relaxation of the lower abdomen. Training will be carried out in two manners: with the patient lying in a left lateral decubitus position with the hip and knee flexed at 90º and sitting. Breathing exercises: With the patient in a seated position, with one hand placed on the abdomen and the other on the thorax, and will be instructed to breath in slowly,. Two series will be completed, with ten repetitions. Abdominal massage: The physiotherapist will perform slow circular clockwise movements, along the line of the colon, with a regular tennis ball, remaining on each point for one minute, beginning with the ascending colon moving in the direction of the sigmoid colon.
Study NCT05380362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous Angioplasty
Description: venous angiogram to look for lesions or flaps and then plastying vessels open.
Study NCT05380362 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Angioplasty
Description: Patients will be brought to the angio suite and will not know if they are having the venous angioplasty or not.
Study NCT03725423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.
Study NCT02753088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-063
Study NCT02753088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone-Teva
Study NCT02753088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00573729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser 577 nm
Description: Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
Study NCT00573729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser 595 nm
Description: Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
Study NCT03468569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Movement Screen
Study NCT00633542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 100 mg/day orally until progression or severe toxicity
Study NCT00633542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon alpha
Description: 3 MU 3 times a week until progression or severe toxicity
Study NCT00830778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticojejunostomy
Description: Pancreaticojejunostomy (PJ) reconstruction/anastomosis
Study NCT00830778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy
Description: Pancreaticogastrostomy (PG) reconstruction/anastomosis
Study NCT04972643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA
Description: EPA 2000mg Soft capsules
Study NCT04972643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: DHA 2000mg Soft capsules
Study NCT04972643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Soft capsules
Study NCT02884700 — intervention group
Intervention type: BIOLOGICAL
Intervention: Real-time PCR testing of lower respiratory tract samples
Description: qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
Study NCT00635076 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
Study NCT00635076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam XR
Description: Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
Study NCT01997112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Study NCT01997112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study NCT02201342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Drug
Study NCT01705015 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PLacebo
Description: UCFit plus encouraged exercise
Study NCT02700451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Age 18-64: Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.~Age 65-75: Intravenous Ketorolac 15 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
Study NCT02700451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
Study NCT02700451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
Study NCT00454207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate (UK-92,480)
Description: sildenafil citrate (UK-92,480)
Study NCT02553135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of AAV2-REP1 (10e11 vg)
Description: Single Group: single arm study
Study NCT02210663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib (ABT-888)
Description: Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
Study NCT01578902 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy
Description: 35Gy/5 fractions/29 days
Study NCT01658267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional supplement
Description: 2 servings per day
Study NCT03247621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whatsapp
Study NCT03247621 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Article
Study NCT03247621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Phone
Study NCT02841488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Use of patient controlled analgesia device with intravenous fentanyl
Study NCT02841488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT00151892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476
Description: 2.4 g/day Once Daily (QD)
Study NCT00151892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol
Description: 1.6g/day administered 800 mg Twice Daily (BID)
Study NCT00708370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COACH
Description: COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.
Study NCT00708370 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention for placebo
Description: There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
Study NCT03883074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid with chondroitin + sulphate + magnesium trisilicate
Description: Melt in mouth tablets (1100 mg)
Study NCT03883074 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets with the same aspect of the active device
Study NCT01889602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam: 2mg, po, 1x
Study NCT01889602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-active placebo, po, 1x
Study NCT01889602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 100mg
Description: Topiramate: 100 mg, po, 1x
Study NCT01889602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 150mg
Description: Topiramate: 150 mg, po, 1x
Study NCT01889602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 200mg
Description: Topiramate: 200 mg, po, 1x
Study NCT00652184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARYS-01 (sorivudine) cream 3% or placebo cream
Description: sorivudine cream 3% or placebo cream twice daily for 10 days
Study NCT00652184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARYS-01 (sorivudine) cream 3% or placebo cream
Description: sorivudine cream 3% or placebo cream twice daily for 10 days
Study NCT00652184 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ARYS-01 (sorivudine) cream 3% or placebo cream
Description: sorivudine cream 3% or placebo cream twice daily for 10 days
Study NCT00652184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo cream and placebo valaciclovir
Study NCT00652184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo cream and placebo valaciclovir
Study NCT00652184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo cream and placebo valaciclovir
Study NCT00652184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: valaciclovir
Description: active valaciclovir
Study NCT00652184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valaciclovir
Description: active valaciclovir
Study NCT00652184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valaciclovir
Description: active valaciclovir
Study NCT00652184 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: valaciclovir
Description: active valaciclovir
Study NCT02107755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV
Study NCT02107755 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery
Study NCT02107755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood and tissue samples will be collected for research purposes.
Study NCT01442181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Surgery
Description: Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.
Study NCT01442181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Patients are treated with rhythm and rate control medications.
Study NCT02841488 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural catheter
Study NCT03283943 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal radiotherapy
Description: Focal sensitizing radiotherapy will be given at a starting dose level of 24 Gray (6 Gy X 4 fractions), and may be escalated to 32 Gy (8Gy X4 fractions).
Study NCT03283943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV every 28 days
Study NCT04937348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Acquisition and analysis of milk samples
Description: In order to ensure reproducible results, breast milk samples were collected using a breast pump. Samples were taken in the morning, after the newborn was breastfed. The entire breast was emptied. In order to ensure the stability of the microbiological and nutritional composition, the milk samples were cooled immediately after collection, and then divided into test tubes and frozen (-80 C) until the laboratory tests were made.~The concentrations of macronutrients (protein, fat, carbohydrate) in breast milk were determined using a Human Milk Analyzer (HMA; Miris, Uppsala). Tissue hormones, e.g. adipokines: visfatin, omentin-1 were determined by ELISA method using commercial reagent kits.
Study NCT00599131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 1. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a \< 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, > 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
Study NCT00599131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 1. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
Study NCT04937348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection, preparation and analysis of mother's blood samples.
Description: Blood samples were collected from the mothers (fasting if possible) on the day the milk samples were taken. After collection, fasting glucose and insulin, as well as glycated hemoglobin were marked, and the other samples were centrifuged and frozen until analyzed (-80 C). Determination of adipokines was performed by ELISA method, using commercial reagent kits.
Study NCT04937348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Body composition assessment
Description: The body composition of newborns was determined by a non-invasive electrical bioimpedance method using the body composition analyzer.
Study NCT04223609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg tablet
Study NCT04223609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oxycodone-matched placebo tablet
Study NCT04223609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeLink 1000 Plus
Description: Non-invasive video-based eye tracking system
Study NCT04937348 — intervention group
Intervention type: OTHER
Intervention: Anthropometric measurements
Description: Based on the mother's medical records, maternal height and pregnancy weight changes were recorded. On the day the biological material is collected, the mother was weighed.~From the baby's documentation, measurements of the length, head circumference and body weight taken after delivery and during the hospitalization were recorded. These measurements were repeated on the days of the body composition analysis.
Study NCT03952143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT03952143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT03952143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study NCT03952143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC
Study NCT03952143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study NCT03952143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC
Study NCT00824148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian REAL-Time Continuous Glucose Monitoring System
Description: One group will use the glucose monitoring system for 1 month
Study NCT00824148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional self-monitoring of plasma glucose
Description: Finger prick blood glucose measurements
Study NCT02609295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.2 g (two capsules) of medium-chain triglyceride (MCT) oil
Study NCT02609295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ALA group
Description: 1.2 g (two capsules) of perilla oil
Study NCT00528606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase clostridium histolyticum
Description: Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
Study NCT00528606 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
Study NCT00599131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
Study NCT00599131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by I.V. over one hour on Day # 1 only
Study NCT01886326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of 42 grams of peanuts daily
Description: Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)
Study NCT04223609 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oculo-Cognitive Addition test (OCAT)
Description: Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.
Study NCT02726581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days, IV (intravenous)
Study NCT02726581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Specified dose on specified days, IV
Study NCT04223609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VT3mini - Eye Tracking Technology for OEMs
Description: Non-invasive eye-tracking device
Study NCT00797420 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole Loading Dose
Description: Single Fluconazole loading dose 25 mg/kg
Study NCT02726581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Specified dose on specified days, PO (by mouth)
Study NCT02726581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Specified dose on specified days, PO (by mouth)
Study NCT00797420 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole Loading Dose & High Dose
Description: Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
Study NCT02726581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Specified dose on specified days, PO
Study NCT02726581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days, PO
Study NCT02495857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronate Injectable Viscosupplement
Description: Test product of a 1% sodium hyaluronate for injection
Study NCT02495857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Euflexxa IA injection
Description: Brand product of a 1% sodium hyaluronate for injection
Study NCT02495857 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride, sterile
Study NCT01833052 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI (Medtronic CoreValve)
Study NCT01833052 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Claret-Filter
Study NCT01352481 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Early parent-based speech intervention program
Description: Seven 1h sessions during a three-month period.
Study NCT04795154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga excercise
Description: Yoga exercise in pre-eclampsia >20 weeks of pregnancy woman, treatment number was 4 times.
Study NCT01629069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness based Resilience Training
Description: 6 weekly group sessions
Study NCT02616809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintaining posture and energy expenditure
Description: Participants will sit continuously for 8-hrs during a simulated office environment